Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic

. 2020 Nov ; 34 (11) : e682-e684. [epub] 20200709

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu dopisy, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid32594549

Zobrazit více v PubMed

Lebwohl M, Rivera‐Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID‐19? J Am Acad Dermatol 2020; 82: 1217–1218. PubMed PMC

Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID‐19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther 2020; e13298. https://di.org/10.1111/dth.13298 PubMed DOI PMC

Julian LJ. Measures of anxiety: state‐trait anxiety inventory (STAI), Beck anxiety inventory (BAI), and Hospital anxiety and Depression scale‐anxiety (HADS‐A). Arthritis Care Res 2011; 63: S467–S472. PubMed PMC

Vangeli E, Bakhshi S, Baker A et al. A systematic review of factors associated with non‐adherence to treatment for immune‐mediated inflammatory diseases. Adv Ther 2015; 32: 983–1028. PubMed PMC

Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population‐based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol 2016; 17: 87–97. PubMed PMC

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...